GREENVILLE, S.C.--(BUSINESS WIRE)--KIYATEC, the leader in clinically correlated, published functional precision oncology technology today announced two key appointments as the Company builds utilization of clinical 3D Predict™ assays and grows its pharmaceutical services portfolio for KIYA-PREDICT™. KIYATEC is pleased to welcome Bruce Yeager as Vice President Market Access & Reimbursement effective March 21, 2022, and Steven Holshouser, Ph.D., as Director, Business Development, effective March 8, 2022.
Chief Executive Officer Matt Gevaert, Ph.D., said, “We are pleased to welcome both Bruce and Steven to our growing team of experienced leaders in their respective fields. Bruce’s significant experience and effectiveness in securing and expanding Medicare and private payer reimbursement and coverage will support the commercialization of 3D Predict™ Glioma and Ovarian assays in 2022 and lays the foundation for reimbursement and coverage plans for our non-small cell lung, rare tumor, and breast cancer assays in the future. Steven’s track record in securing pharmaceutical services contracts will expand revenues from our growing portfolio of clients using KIYA-PREDICT™ therapeutic response and 3D cell culture technology applications in their drug development plans.”
KIYATEC’s clinical and pre-clinical technology platforms, 3D PredictTM and KIYA-PREDICTTM, respectively, are leading the functional precision oncology space with published evidence of predictive response correlated to clinical outcomes. Recently the Company represented its 3D Predict™ Ovarian publications at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer and announced six abstract acceptances to be presented at the American Association for Cancer Research from April 8-13, 2022 in New Orleans.
About KIYATEC
KIYATEC is a functional precision oncology company that measures the response of individual patient live cancer cells with its innovative 3D cell culture technology platform. The Company offers clinical tests for high-grade glioma and is developing tests for ovarian, breast, non-small cell lung and rare tumors in its CLIA-certified lab. The Company works with leading biopharmaceutical companies to unlock response dynamics for their investigational drug candidates across the majority of solid tumor types. For more information, visit www.KIYATEC.com and connect with us on LinkedIn and Twitter.
